Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer

AI is making strides with its ability to process large amounts of data quickly using organizational platforms and tools that make information more accessible than ever.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

There is currently 1 FDA-approved antibody-drug conjugate available for patients with non-small cell lung cancer, and several more potentially coming down the pike.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Recommendations for non–small cell lung cancer biomarker testing in early-stage disease were discussed in a presentation regarding metastatic lung cancer by Christine M. Lovly, MD, PhD.

Findings from recent clinical research have firmly entrenched the use of neoadjuvant immune checkpoint blockade in the treatment of early-stage non-small cell lung cancer.